Pevifoscorvir Sodium (ALG-000184)
Sponsors
Aligos Therapeutics
Conditions
Chronic Hepatitis B InfectionChronic Hepatitis B Infections
Phase 1
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
CompletedNCT07342881
Start: 2026-03-10End: 2026-07-29Updated: 2026-08-21
Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
CompletedNCT07342868
Start: 2026-01-30End: 2026-08-19Updated: 2026-08-21